Sharon Bola is a global product manager with the process chromatography business group at Bio-Rad Laboratories. She holds a master's degree in pharmacology. Prior to transitioning into her current role, she started her career working in downstream processing groups at major biopharmaceutical companies. She has had hands-on experience in the purification of proteins including monoclonal antibodies (mAbs). She is a content marketer at Bio-Rad and enjoys teaching and understanding customer’s needs.
About this event:
Date:February 12, 2026
Time:11 am EST | 8 am PST | 5 pm CET
Duration:15 minutes
Antibody-drug conjugates (ADCs) are transforming the landscape of biotherapeutics by harnessing the precision of monoclonal antibodies and the power of cytotoxic drugs. Ensuring the purity of ADCs is essential, as product-related impurities—such as high molecular weight aggregates and variants with elevated drug-to-antibody ratios (DARs)—can compromise both safety and efficacy.
Join Bio-Rad Laboratories as they explore the purification of an emtansine biosimilar ADC using a mixed-mode media. Discover how unique mixed-mode interaction enables effective separation of monomeric ADCs from aggregates and over-conjugated species. Bio-Rad's process development studies reveal robust aggregate clearance and enrichment of the desired DAR profile, with optimized parameters for resin loading, elution, and scalability.
This webcast will demonstrate how ceramic hydroxyapatite chromatography offers a scalable, reproducible solution for improving product quality and consistency in both biosimilar and novel ADC manufacturing.
